Callan JMB to Break Ground on IV Bag Manufacturing Facility Fully Funded by Non-Dilutive and Non-Interest-Bearing Third-Party Partnership
Key Highlights
- ➤$16 million facility fully funded through non-dilutive, non-interest-bearing third-party partnership
- ➤Construction expected before October ends following formal blueprint approval
- ➤Facility projected to generate $450 million annual revenue once operational
- ➤Standard IV bags projected at $300 million annual revenue
- ➤Premixed drug IV bags projected at $150 million annual revenue
Expert Statements
Wayne Williams, Chief Executive Officer of Callan JMB
“Achieving blueprint approval was a critical milestone, and we are moving quickly to break ground and begin construction on the facility this month. This facility is backed fully by a third-party investment that will not add debt to Callan JMB’s balance sheet nor is dilutive to Callan JMB shareholders. This project builds on our healthcare logistics and emergency-preparedness experience while supporting the strengthening of the United States (U.S.) domestic pharmaceutical production, enhancing U.S. supply chain resilience, and improving national security through medical preparedness.”
The non-dilutive $16 million capital investment from a third party for Atlas Complex construction advances Callan JMB’s pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain preparedness
SPRING BRANCH, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified preparedness, logistics, and critical-infrastructure company, today is providing shareholders with a timeline to break ground on an intravenous (IV) bag manufacturing and distribution facility at the Atlas Complex in Marion, Alabama. The $16 million facility will be fully funded by a third party through a non-dilutive, non-interest-bearing partnership.
Get started
Create a free account to read the full story.